COVID-19

ACTIVITIES

92732813_xl.jpg
22 September 2020

Amarex to Support AIM ImmunoTech in Regulatory Filings for Exciting Pancreatic Cancer Treatment under Development

Amarex Clinical Research, LLC (Amarex) client AIM ImmunoTech Inc. (NYSE American: AIM) today announced receipt of statistically significant positive pancreatic cancer survival results from a multi-year Early Access Program (EAP) conducted at Erasmus Medical Center in the Netherlands.

88710562_l.jpg
21 September 2020

Now Enrolling for a Phase IIb Trial Treating Patients with HPV-Induced CIN2/3

Amarex Clinical Research, LLC, an NSF International company announces its client, Frantz Viral Therapeutics, LLC, is now enrolling for their Phase IIb pivotal clinical trial of Artesunate Vaginal Inserts for the treatment of biopsy-proven HPV-associated cervical intraepithelial neoplasia 2/3 (CIN2/3) in adult female patients.

63442525_l.jpeg
16 September 2020

2020 Bio Innovation Conference | Oct. 5-6

Dr. Kazem Kazempour, Amarex President & CEO, will present virtually at Bio Innovation on October 6. He will discuss Business Resiliency for the Unexpected and Expected. Amarex will also exhibit at this conference. 

34536473_xl.jpeg
10 September 2020

Amarex Receives SMP Letter from TFDA for an Oncology Drug Clinical Trial Treating Pancreatic Cancer

Amarex Clinical Research, LLC, an NSF International company announces today that earlier this week they received a study may proceed (SMP) letter from the Taiwan Food & Drug Administration (TFDA) to conduct the first in human clinical trial of RP-72 in Taiwan.

As a full-service, international CRO, Amarex Clinical Research has extensive experience successfully performing clinical studies across all phases of research and discovery, development, validation and approval.​​​

Recommended by the people who matter most: our clients.

 

Chief Medical Officer 

A Maryland Biotech Company

We have worked with Amarex on numerous projects and they consistently deliver high quality reliable service by leveraging a broad array of clinical and regulatory expertise. What sets them apart from other CROs is a creative entrepreneurial approach to drug development. They go beyond the technical aspects of clinical trial development and work with the sponsor to drive value and increase chances for success.

        

             5/5

Chief Technical Officer

A Canadian-based Infectious Diseases Organization

[Thank you to the team at Amarex] for the statistical support which proved to be invaluable and completely accurate in the final review by FDA. The cornerstone of this milestone achievement was the data from the clinical study, including the limit of detection study, and we came through [all FDA reviews with solid outcomes throughout]. From all of us here, a sincere thank you and well done to all at Amarex who worked on this project. We look forward to working with you again as we apply the successful platform to other diagnostic device developments in the future.

        

             5/5

VP, Clinical Development

A Canadian Device Company

To this focused and hard-working team: I count myself lucky to work with such caring individuals.Thanks for being some of the most interesting and high performing people I've ever worked with.

        

             5/5

AMAREX_NSF_1C.png
  • Facebook Social Icon
  • Twitter Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon

           

           © 2020 Amarex Clinical Research, LLC, an NSF International company. All rights reserved.                                                                                                                                                                                                  Top of Page 

Contact     Subscribe     Privacy Policy     Clinical Site Registration     WebView

NSF Mark_100x100.jpg